Literature DB >> 10798767

Decreased donor-specific cytotoxic T cell precursor frequencies one year after clinical lung transplantation do not reflect transplantation tolerance: a comparison of lung transplant recipients with or without bronchiolitis obliterans syndrome.

A de Haan1, I van der Gun, B G Hepkema, W J de Boer, W van der Bij, L F de Leij, J Prop.   

Abstract

BACKGROUND: Decreased in vitro T cell alloreactivity, demonstrated by decreased frequencies of peripheral blood donor-specific T cell precursors, may reflect a tolerant state after transplantation and lower the risk for development of chronic graft dysfunction. It is unknown whether a decrease in donor-specific T cell frequencies also occurs after clinical lung transplantation and if such a decrease lowers the risk for bronchiolitis obliterans syndrome (BOS), a hallmark of chronic graft dysfunction. Therefore, we compared changes in posttransplant donor-specific cytotoxic T lymphocyte (CTLp) and helper T lymphocyte precursor (HTLp) frequencies in lung allograft recipients with good graft function and in recipients with BOS.
METHODS: Donor and third party specific CTLp and HTLp frequencies were determined by limiting dilution assay in pre- and posttransplant (1 year) peripheral blood samples of lung allograft recipients with good graft function (n = 13) and BOS (n = 10).
RESULTS: In recipients with good graft function, mean donor-specific CTLp frequencies decreased after transplantation (183 vs. 16 precursors before and after transplantation, respectively). Additionally, HTLp frequencies decreased but this was not specific for donor alloantigens because third party-specific HTLp frequencies decreased also. Surprisingly, recipients with BOS also showed a decrease in mean donor-specific CTLp frequencies after transplantation (332 vs. 49 precursors before and after transplantation, respectively). Again, HTLp frequencies decreased nonspecifically.
CONCLUSIONS: We conclude that donor-specific CTLp frequencies decrease after lung transplantation, but that this does not result in transplantation tolerance protecting the lung against the development of chronic graft dysfunction.

Entities:  

Mesh:

Year:  2000        PMID: 10798767     DOI: 10.1097/00007890-200004150-00038

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans.

Authors:  Pervinder Sagoo; Esperanza Perucha; Birgit Sawitzki; Stefan Tomiuk; David A Stephens; Patrick Miqueu; Stephanie Chapman; Ligia Craciun; Ruhena Sergeant; Sophie Brouard; Flavia Rovis; Elvira Jimenez; Amany Ballow; Magali Giral; Irene Rebollo-Mesa; Alain Le Moine; Cecile Braudeau; Rachel Hilton; Bernhard Gerstmayer; Katarzyna Bourcier; Adnan Sharif; Magdalena Krajewska; Graham M Lord; Ian Roberts; Michel Goldman; Kathryn J Wood; Kenneth Newell; Vicki Seyfert-Margolis; Anthony N Warrens; Uwe Janssen; Hans-Dieter Volk; Jean-Paul Soulillou; Maria P Hernandez-Fuentes; Robert I Lechler
Journal:  J Clin Invest       Date:  2010-05-24       Impact factor: 14.808

2.  Down-regulated donor-specific T-cell reactivity during successful tapering of immunosuppression after kidney transplantation.

Authors:  N M van Besouw; B J van der Mast; P de Kuiper; P J H Smak regoor; Lenard M B Vaessen; J N M Ijzermans; T van Gelder; W Weimar
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

3.  Detailed kinetics of the direct allo-response in human liver transplant recipients: new insights from an optimized assay.

Authors:  Ozlem Tapirdamaz; Shanta Mancham; Luc J W van der Laan; Geert Kazemier; Kris Thielemans; Herold J Metselaar; Jaap Kwekkeboom
Journal:  PLoS One       Date:  2010-12-29       Impact factor: 3.240

4.  Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation.

Authors:  Pervinder Sagoo; Giovanna Lombardi; Robert I Lechler
Journal:  Front Immunol       Date:  2012-07-13       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.